Dr. Winkler has led until recently the business development of Pharmaseed in the past 6 years, leading it’s expansion and moving into new areas such as cannabis and toxicology and gaining several new clients from the global pharma industry. He has over 15 years of hands-on experience in the pharmaceutical and drug-development industry, specializing in bio-pharmaceuticals, preclinical studies, pharmacokinetics and the development of new drugs. In his former position Dr. Winkler served as a VP Preclinical Development at LipoCure. Dr. Winkler has published numerous scientific papers and patents, mainly concerning the development of therapeutic agents for treating disorders of the central nervous system. Dr. Winkler earned his Ph.D. at the Hebrew University of Jerusalem School of Pharmacy.
Prof. Ronnie Levy joined Pharmaseed in 2010 and serves as Chief Science Officer as well as liaison to Pharmaseed’s Scientific Advisory Board. Prof. Levy was the Head of the Radiochemistry Department at the Nuclear Research Center in the Negev (NRCN) for 13 years (1965-1973). During the years 1977 and 2007 he served at the Israel Institute of Biological Reseach (IIBR), 13 of those years as Head of the Pharmacology Department. Professor Levy holds a PhD degree of the Hebrew University in chemistry, post-doc training in pharmacology at the Roche Institute for Molecular Biology and a full professor nomination at Ben-Gurion University, Beer-Sheva. Prof. Levy attended several Sabbaticals where he conducted research activities at renowned institutes. Between 1995 and 2000 Prof. Levy served on the Board of Directors of the Dead Sea Bromine Group as head of the Research Committee.
Anna Goishan joined Pharmaseed in March of 2017 as office manager and had of facility manager. Anna has over 11 years of operational experience. Prior to Pharmaseed she served as office manager at Tnuva and Office Depot. Including administration and operation of 1200 employees . Anna has MBA at business management. Anna is currently in charge of all operations and administration, including finance, human resources, procurement, facility management.
Dr. Meital Brami joined the preclinical unit of Pharmaseed in 2016 as a Study director. Later, she assumes the role of Head of the preclinical unit and since June 2020 serves as the VP R&D. Meital holds a first degree in Chemical Engineering and a PhD in Biotechnology Engineering from the Ben Gurion University (BGU)- Negev. In her past positions, Meital served as an External Lecturer in the Biotechnology Engineering Department of BGU and as a Laboratory Manager in the Sackler Faculty of Medicine, at the Tel-Aviv University. She has specialized in various of methods exploring the immune system in vitro and in vivo. Meital is currently in charge of all the preclinical unit activities at Pharmaseed including development of new capabilities.
VP of Quality Assurance
Einat Souli joined Pharmaseed in 2019 and serves as the VP QA.
Einat worked in various roles at Teva Pharmaceutical Industries R&D unit for more than 13 years, including a Project Leader for screening and ADME/PK studies, Pre-clinical Project Manager in the non-clinical safety department, QA for pre-clinical regulatory submissions and pre-clinical safety studies. In addition, worked in a biotechnology company as a QA Director and Pre-clinical Manager. Einat holds a M.Sc. and Eng. in Food and Biotechnology Engineering from the Technion-Israel Institute of Technology, Haifa.